Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Understanding Ghana's FDA and pharmacovigilance regulations

Priscilla Aduse-Poku

Understanding Ghana's FDA and pharmacovigilance regulations ( Priscilla Aduse-Poku )

Understanding Zimbabwe's pharmacovigilance system

Liberty Chirinda - Medicines Control Authority of Zimbabwe, Harare, Zimbabwe

Understanding Zimbabwe's pharmacovigilance system ( Liberty Chirinda - Medicines Control Authority of Zimbabwe, Harare, Zimbabwe )

ASCO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Cost comparison of IV vs subcutaneous trastuzumab in HER2+ breast cancer in...

Dr Kunvar Harsh Upveja - Biocon Biologics, Bengaluru, India

Cost comparison of IV vs subcutaneous trastuzumab in HER2+ breast cancer in Morocco ( Dr Kunvar Harsh Upveja - Biocon Biologics, Bengaluru, India )

Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma...

Dr Zeynep Eroglu - Moffitt Cancer Center, Tampa, USA

Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma brain metastases ( Dr Zeynep Eroglu - Moffitt Cancer Center, Tampa, USA )

Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in...

Dr Ahmad Tarhini - Moffitt Cancer Center, Tampa, USA

Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in high-risk resectable melanoma ( Dr Ahmad Tarhini - Moffitt Cancer Center, Tampa, USA )

ASCO 2025: Importance of early testing in metastatic prostate cancer

Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida...

ASCO 2025: Importance of early testing in metastatic prostate cancer ( Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano )

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC

Dr David Braun - Yale School of Medicine, New Haven, USA

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC ( Dr David Braun - Yale School of Medicine, New Haven, USA )

Tumour microenvironment and circulating biomarkers predict response to...

Dr David Braun - Yale School of Medicine, New Haven, USA

Tumour microenvironment and circulating biomarkers predict response to immunotherapy in advanced RCC ( Dr David Braun - Yale School of Medicine, New Haven, USA )

Catequentinib improves PFS vs placebo in advanced or metastatic leiomyosarcoma

Prof Robin Lewis Jones - The Royal Marsden, London, UK

Catequentinib improves PFS vs placebo in advanced or metastatic leiomyosarcoma ( Prof Robin Lewis Jones - The Royal Marsden, London, UK )

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial...

Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer ( Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy )

ASCO 2025: Metastatic breast cancer treatment highlights

Dr Maryam Lustberg - Yale School of Medicine, New Haven, USA

ASCO 2025: Metastatic breast cancer treatment highlights ( Dr Maryam Lustberg - Yale School of Medicine, New Haven, USA )

More from ecancer